Amgen targets physicians with biosimilars education campaign in advance of expected 2023 breakout
With 2023 poised to be a big year for biosimilars, Amgen is marketing to doctors to help them understand the biologic drugs — and get ready for patient questions.
Why will people be asking more about biosimilars this year? The main reason is AbbVie’s megablockbuster Humira will get its first biosimilar competition in the US at the end of January, followed by a raft of other Humira biosimilars launching throughout the year. While that first Humira competitor is Amgen’s own Amjevita, its biosimilar social media campaign is educational only and does not include any mention of its own products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.